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A Ray of Hope
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Abstract
Most viral infections have limited treatment options available and the same 
holds for COVID-19, its causative agent being the SARS-CoV-2 virus. Drugs used 
in the past against Severe Acute Respiratory Syndrome (SARS) or Middle East 
Respiratory Syndrome (MERS) viruses, which belong to the same family of viruses 
as the novel Coronavirus included ribavirin, interferon (alfa and beta), lopinavir-
ritonavir combination, and corticosteroids. There remains controversy regarding 
their efficacy to date, except for the last one. Hence, large-scale multicentric trials 
are being conducted involving multiple drugs. Chloroquine and hydroxy-chloro-
quine were initially taking the race ahead but have now been rejected. Remdesivir 
was a promising candidate, for which the FDA had issued an emergency use autho-
rization, but now is not recommended by the WHO. Convalescent plasma therapy 
had promising results in the early severe viremia phase, but the PLACID trial 
made an obscure end. Only corticosteroids have shown demonstrable benefits in 
improving mortality rates among severe COVID-19 cases. Many new modalities like 
monoclonal antibodies and tyrosine kinase inhibitors are discussed. In this chapter, 
we review the therapeutic drugs under investigation for the COVID-19 treatment, 
their mode of action, degree of effectiveness, and recommendations by different 
centers regarding their use in current settings.
Keywords: antiviral, monoclonal antibody, coronavirus disease 2019, 
dexamethasone, immunomodulator, ivermectin, remdesivir
1. Introduction
Because of the high rate of infectivity of the COVID-19 virus, the global 
burden associated with the disease, and its impact on the economies of different 
countries, efforts are being made to find a possible cure for the disease as soon as 
possible. [1] As with most viral infections, limited options are available for the 
treatment of COVID-19. Since there is no efficient therapy available for the same, 
given the public emergency, efforts are ongoing to find drugs helpful in COVID-
19 infection. Drugs used in the past against Severe Acute Respiratory Syndrome 
(SARS) or Middle East Respiratory Syndrome (MERS), which also belong to the 
group of Beta coronaviruses, included ribavirin, interferon, lopinavir-ritonavir, 
and corticosteroids. [2] Most randomized controlled trials (RCTs) performed 
to test the effectiveness of these drugs have not shown any satisfying results, 
apart from corticosteroids. Many RCTs are still undergoing, the results of which 
are awaited. Studies about the virus-induced host immune response and viral 
processing within target cells have led to several potential therapeutic targets. 
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Figure 1. 
Site of action of different possible pharmacotherapeutics used in COVID-19 treatment.
Drug Mode of action Effectiveness Recommendation
Corticosteroids Immunosuppressant Decreased death rate 
in ARDS, no effect in 
non-ARDS
WHO, CDC, and IDSA 
recommendations
Remdesivir RdRp inhibitor Decreases recovery 
time
FDA approval in October, 
WHO issued a conditional 
recommendation against 




Anti-COVID 19 antibodies No benefit FDA EUA issued
Monoclonal 
antibodies
Directed against COVID 
spike proteins
Benefit in Mild 
cases, no benefit in 
hospitalized cases
FDA EUA issued for OPD 
patients
Azithromycin Immunomodulation No benefit No recommendation, but 
widely used
Ivermectin Viral IMPα/β1(Importin) 
mediated nuclear import 
inhibition
Benefit in prophylaxis NIH: Insufficient data for or 
against the use
Melatonin Pineal gland hormone, 
anti-inflammatory
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We hereby discuss the potential therapeutic drugs under investigation for the 
COVID-19 treatment, their modes of action (Figure 1), degree of effectiveness, 
and recommendations (Table 1) by different centers regarding their usage in the 
current settings.
2. Review of pharmacotherapy
2.1 Chloroquine/hydroxychloroquine
The first studied drugs for COVID-19 were chloroquine and hydroxychloro-
quine (HCQ ). Chloroquine was found to be effective against Avian influenza A 
H5N1 virus in animal models [3, 4] and also had demonstrable activity resulting in 
in-vitro inhibition of SARS-CoV. [5] COVID-19 infection showed high pandemic-
ity in countries where malaria is the least prevalent and least pandemicity where 
malaria is highly prevalent. This observation led to the concept that chloroquine 
may be beneficial in COVID-19 since it is used as an anti-malarial. The mechanism 
of chloroquine action depends on the pathogen involved. Chloroquine increases the 
endosomal pH and interferes with the glycosylation of cellular receptor [Angiotensin 
Converting Enzyme (ACE) II] of SARS-CoV. [6] It also inhibits quinone reductase-2, 
which is involved in sialic acid biosynthesis. There is inhibition of MAO-kinase, 
virion assembly, and processing of M protein. [7] Besides its antiviral activity, it 
also has immunomodulatory effects that may be synergistic. HCQ was found to be 
Drug Mode of action Effectiveness Recommendation
Tocilizumab IL-6 R inhibitor Reduces inflammatory 
markers
Single-dose in addition 
to dexamethasone in 
critical patients with rapid 
progression of respiratory 
failure may be given: NIH









pH, interfere with 
glycosylation of receptor, 
immunomodulator








Protease inhibitor: SARS- 
Cov-2 3CL pro
Not significant Removed from 
Solidarity trial, no other 
recommendation
Interferon Immunomodulation No concrete evidence Removed from 








No concrete evidence Use with remdesivir 
if corticosteroids are 
contraindicated: NIH/IDSA
RdRp: RNA dependent RNA polymerase; ARDS: Acute respiratory distress syndrome; WHO: World Health 
Organization; CDC: Centers for Disease Control and Prevention; FDA: Food and Drug Administration; IDSA: 
Infectious Disease Society of America; EUA: Emergency Use Authorization; NIH: National Institute of Health;  
Il-6 R: Interleukin-6 receptor; STAT: Signal transducer and activator of transcription.
Table 1. 
Summary of various pharmacotherapeutics being considered for COVID-19 treatment.
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equally effective as chloroquine, although a study concluded that HCQ was more 
effective and less toxic than chloroquine. [8] Chloroquine inhibitory actions against 
SARS-CoV were equal whether the primate cells were treated before or after expo-
sure. This suggested that chloroquine could have both prophylactic and therapeutic 
applications. [9] One of the first studies performed to study the effect of chloroquine 
was done in the Chinese population. In this trial, patients in the study group who 
received chloroquine had reduced symptom duration, radiological improvement, 
and earlier seroconversion to the virus-negative state compared to controls. [10] 
Following this study, the National Health Commission of the People’s Republic of 
China included chloroquine in its guideline for the management of pneumonia due 
to Covid-19. In a study conducted by Gautret et al. in France, chloroquine treatment 
group had significant clearing of the nasopharyngeal swab viral load compared to 
the control. [11] The virological clearance day-6 post inclusion (primary outcome) 
with HCQ vs. controls was 70% vs. 12.5% (p < 0.001). The virological clearance at 
day 6 in HCQ plus azithromycin, HCQ and control arms were 100%, 57.1%, and 
12.5% respectively (p = 0.001) thus suggesting synergistic action of azithromycin 
to HCQ . Gradually the side effect profile of HCQ , that is QTc prolongation with 
concomitant use of Azithromycin, lead the American Heart Association (AHA) to 
recommend withdrawal/withholding these drugs in patients with QTc ≥ 500 mil-
lisecond (either baseline or developing during treatment). On 28 March 2020, Food 
and Drug Administration (FDA) had issued Emergency Use Authorization (EUA) 
for Chloroquine/HCQ . However, the Centers for Disease Control and Prevention 
(CDC) on April 7 issued a statement stating no drugs or other therapeutic measures 
were approved by the US FDA to prevent or treat COVID-19. In April, the FDA issued 
a Drug Safety Communication cautioning against the use of HCQ or chloroquine 
for COVID-19 outside the hospital setting or a clinical trial due to the risk of heart 
rhythm problems. In June 2020, it was announced by World Health Organization 
(WHO) that the HCQ arm of the Solidarity Trial (Multi-national trial including 
remdesivir, HCQ , lopinavir/ritonavir, and lopinavir/ritonavir with interferon beta-
1a) would be stopped. [12] This was keeping in view the lack of any mortality benefit 
of HCQ . Hence in June itself, FDA revoked the EUA of HCQ and chloroquine. [13] 
The pre-exposure prophylaxis benefit of HCQ needs further research.
2.2 Lopinavir/ritonavir
The combination of lopinavir/ritonavir was considered as an option for the 
treatment of Covid-19 during initial pandemic days. Lopinavir is an HIV-1 protease 
inhibitor, which is combined with ritonavir to increase its half-life through cyto-
chrome p-450 inhibition. Both anti-HIV drugs interact with residues at the active 
site of SARS-CoV 3C-like protease, suggesting the mechanism of action in COVID-
19. [14] Its role was first evaluated in the treatment of SARS where patients treated 
with lopinavir/ritonavir for 14 days combined with ribavirin for 21 days. They had 
a milder disease in form of less diarrhea, fever, lymphadenopathy, the incidence of 
nosocomial infections, viral loads, demonstration of virus in the fecal sample by 
reverse transcription-polymerase chain reaction (RT-PCR), and 21 days adverse 
outcomes. [15] The combination was tested for MERS-CoV. It was postulated that 
the lopinavir/ritonavir combination may inhibit the 3C-like protease of MERS-CoV 
and may affect apoptosis in human cells. Results revealed that treatment with lopi-
navir/ritonavir led to clinical, radiological, and pathological improvement. Those 
animals treated with this combination had the lowest mean viral load detected 
by RT-PCR in lung and other extrapulmonary tissue. [16] There was only a single 
case report of a man being treated and recovered with a combination of lopinavir/
ritonavir, ribavirin, and interferon-α for the MERS. [17] Based on this data, an 
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urgent RCT was done to study the efficacy of lopinavir/ritonavir in the Wuhan 
province of China. [18] The analysis revealed no significant difference in terms of 
time for clinical improvement and mortality at 28 days. The median time for clinical 
improvement was just one day shorter in the lopinavir-ritonavir group compared 
to the standard care group. In July 2020, WHO discontinued the lopinavir/ritonavir 
arm of the solidarity trial due to a lack of any mortality benefit. [19] It causes QTc 
prolongation, just like HCQ . [20]
2.3 Azithromycin
Azithromycin is a broad-spectrum antibiotic belonging to the macrolide group, 
having anti-inflammatory properties also. It is commonly used for treating atypi-
cal respiratory pathogens. Azithromycin’s anti-viral efficacy against some RNA 
viruses has also been described. Its efficacy has been demonstrated in-vitro against 
Zika virus and rhinovirus, as well as SARS-CoV-2. [21, 22] As described, azithro-
mycin also has immunomodulatory effects and can decrease acute exacerbations 
of chronic airway disease. Owing to its wide availability, excellent safety profile, 
and easy availability, azithromycin is one of the commonest drugs being used in 
the COVID-19 pandemic also. The Lancet reported the result of the COALITION 
II trial, [23] which was an open-label randomized trial evaluating azithromycin 
in addition to the standard of care (including HCQ ), against the standard of care 
alone in severe COVID-19 patients. Azithromycin demonstrated no benefit in 
clinical outcome including clinical status or mortality, as compared to the standard 
of care alone (OR 1·36 [95% CI 0·94–1·97], p = 0·11). There was no increase in 
adverse events with azithromycin. In a study published in NEJM, HCQ alone or 
in combination with azithromycin had no demonstrable improvement in clini-
cal status at 15 days compared with standard care in mild to moderate COVID-19 
admissions. [24]
2.4 Ivermectin
Ivermectin is a commonly used drug for various parasitic infestations includ-
ing head lice, scabies, strongyloidiasis, ascariasis, and lymphatic filariasis. It 
is a macrocyclic lactone, which is derived from streptomyces avermitilis. [25] 
Its mechanism of activity against SARS-CoV-2 is believed to be via viral IMPα/
β1 (Importin) mediated nuclear import inhibition. This leads to a decrease in 
the multiplication of the virus and hence the viral load. [26, 27] Ivermectin and 
doxycycline combination also inhibit viral entry and increases viral load clear-
ance by the targeting of multiple viral proteins. [28] A recent study from India 
demonstrated that 2-dose ivermectin prophylaxis (300 micrograms/kg) within 
a gap of 3 days led to a 73% reduction in the number of COVID-19 infections 
among healthcare workers. [29] In studies conducted in Bangladesh also, the 
ivermectin-doxycycline combination was demonstrated to be highly effective in 
virological clearance in mild to moderate COVID-19 patients. [30, 31] National 
Institute of Health (NIH) stated in January 2021 that there was insufficient data 
to recommend either for or against the use of ivermectin for the treatment of 
COVID-19. [32]
2.5 Melatonin
Melatonin is a hormone, which is synthesized from tryptophan in the pineal 
gland of the body and also by mostly all the organs of the body, as its production 
is associated with mitochondria. Higher levels of melatonin have positive roles in 
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health and aging. Melatonin promises to be a great adjunctive drug for viral infec-
tions owing to its anti-inflammatory, anti-apoptotic, immunomodulatory, and 
antioxidant activities. [33] Sirtuin-1 (SIRT1) is the proposed mediator of melato-
nin’s anti-inflammatory action. This is via inhibition of high mobility group box-
echromosomal protein-1 (HMGB-1), leading to down-regulation of the polarization 
of macrophages towards pro-inflammatory type. [34] It inhibits the over-activity 
of the innate immune system. Hence, theoretically, the cytokine storm induced by 
COVID-19 can be suppressed by melatonin. But the use of melatonin in COVID-
19 is still very sparse, with only a few studies evaluating the same, hence further 
research is warranted. [35] Owing to melatonin’s anti-inflammatory, anti-oxidant, 
and anti-viral actions, its role in critical illness caused due to COVID has been 
studied. Melatonin has easy availability, is not expensive, and has an excellent safety 
profile. [36] A trial (EudraCT: 2020–001808-42) is ongoing for the identification 
of the doses of melatonin that may prove effective in this disease. It is a phase II, 
single-center, double-blind, RCT to address the efficacy and safety of intravenous 
melatonin in COVID-19 ICU patients. [37]
2.6 Remdesivir
Remdesivir is a 1′-cyano-substituted adenosine nucleotide analog prodrug, 
which was found to be effective against several RNA viruses. It was initially devel-
oped in 2017 by Gilead science for the treatment of the Ebola virus. [38] It has 
demonstrated extensive antiviral activity & effective treatment of lethal Ebola and 
Nipah virus infections in nonhuman primates. [39] Subsequently, it was investi-
gated for SARS-CoV and MERS-CoV. Studies have shown that Remdesivir inhibits 
viral replication in human airway epithelial cell culture by affecting the early stages 
of viral replication through viral RNA synthesis inhibition, as an RNA-dependent 
RNA polymerase (RdRp) inhibitor. [39] This may be due to the absence of Exon-
mediated proofreading in viruses sensitive to Remdesivir. [40] One of the first trials 
of Remdesivir was performed by the Gilead sciences center in hospitalized patients 
with confirmed SARS-CoV-2 having oxygen saturation < 94% or a need for oxygen 
support. Till 28 days of follow-up, the cumulative incidence of clinical improvement 
was 84% (95% CI 70–99) by Kaplan–Meier analysis and it was less among patients 
receiving invasive ventilation compared to non-invasive ventilation. [41] In another 
randomized, double-blind, placebo-controlled, multicentre trial at 10 hospitals 
in Hubei, China, Remdesivir use was not associated with any difference in time to 
clinical improvement. [42] In February 2020, WHO cast a vote of confidence for 
remdesivir, indicating that it has great potential. In April 2020, the US National 
Institute of Allergy and Infectious Diseases (NIAID), announced that a clinical 
trial in >1,000 people showed that those taking remdesivir recovered in 11 days on 
average, compared with 15 days for those on a placebo, even adding that remdesivir 
may become a standard for COVID treatment. [43] US FDA had issued a EUA for 
remdesivir for severe COVID-19 disease. On 22nd October 2020, the FDA approved 
remdesivir for use in adult and pediatric patients (≥12 years, ≥40 kg) requiring 
hospitalization. [44] In October 2020 itself, an interim analysis of the WHO-led, 
open-label, randomized SOLIDARITY trial demonstrated that 301 (11·0%) of 2743 
patients who received remdesivir and 303 (11·2%) of 2708 patients who received 
standard care died by day 28 (Kaplan–Meier rate ratio 0·95, 95% CI 0·81–1·11; 
p = 0·50). [45] The ACTT-1 study had also reported a 29-day mortality of 11·4% 
in patients receiving remdesivir as compared to 15·2% in placebo (hazard ratio 
0·73, 95% CI 0·52–1·03). [43] Hence in November 2020, WHO issued a conditional 
recommendation against remdesivir utilization in hospitalized patients, regardless 
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of their disease severity. This was because they could not find evidence of remdesi-
vir improving survival and other outcomes in the patients. [46] Infectious Disease 
Society of America (IDSA) still suggests the use of remdesivir in severe and critical 
patients, as does NIH. [47, 48]
2.7 Tocilizumab
Tocilizumab is an Interleukin-6 (IL-6) Receptor inhibiting monoclonal anti-
body. Studies have shown that infection with the SARS virus leads to a cytokine 
storm with the release of inflammatory cytokines like IL-6, Tumor Necrosis 
Factor- α (TNF –α), and IL-12. [49] Further research done on MERS-CoV showed 
IL-6, IL-1β, and IL-8 were elevated in these patients. In patients with confirmed 
COVID-19 infection who were admitted to ICU, levels of IL-2, IL-6, IL-7, IL-10, 
granulocyte-colony stimulating factor (G-CSF), interferon-γ-inducible protein 
(IP10), monocyte chemoattractant protein (MCP1), macrophage inflammatory 
protein 1 alpha (MIP1A), and TNF-α levels were found to be high, suggesting pos-
sible cytokine storm. [50] The first trial involving tocilizumab was performed in 
China in February 2020. The National Institute for Infectious disease had recom-
mended tocilizumab in moderate to severe infections and IL-6 levels >40 pg/mL 
(or D-dimer levels >1000 ng/mL). However, it is not recommended by the CDC. 
In an RCT published in JAMA, in moderate-to-severe pneumonia, tocilizumab did 
not reduce the WHO Clinical Progression Scale scores. The proportion of patients 
with non-invasive or invasive ventilation or death at day 14 was 36% with usual 
care and 24% with tocilizumab. There were no differences in 28 days mortal-
ity. This meant tocilizumab could decrease the requirement for mechanical and 
non-invasive ventilation or death by day 14 but not mortality by day 28. [51, 52] 
An RCT published by NEJM in October 2020, which included patients fulfilling 
at least two of the following: fever, pulmonary infiltrates, or the need for oxygen 
therapy to maintain oxygen saturation more than 92%, concluded that tocilizumab 
was not effective in preventing intubation or death in moderately ill hospitalized 
patients with Covid-19. [53] Sarilumab, another IL-6 receptor antagonist was being 
tested in a multicentre trial for hospitalized patients with severe COVID-19. [54] 
It was concluded that at 28 days, clinical improvement and mortality in severe 
COVID-19 were not significantly different between sarilumab and standard of 
care. [55] Preliminary results from the Randomized, Embedded, Multifactorial 
Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) 
were released in a non-peer-reviewed report. REMAP-CAP is the largest trial to 
date investigating the use of IL-6 inhibitors in COVID-19. In February 2021, after 
reviewing the evidence from REMAP-CAP and other trials, the NIH Panel revised 
the recommendations on the use of tocilizumab and sarilumab, stating there was 
insufficient data to recommend either for or against the use of these drugs. But 
given the REMAP-CAP trial, some members suggested administering a single 
dose of tocilizumab (8 mg/kg of actual body weight, max 800 mg) in addition to 
dexamethasone in the ICU patients having high oxygen requirements/invasive and 
non-invasive mechanical ventilation and exhibiting rapid progression of respira-
tory failure. [56] The number of patients receiving sarilumab in the REMAP-CAP 
trial was too low to assess the efficacy.
2.8 Convalescent plasma
There was a hypothesis that plasma collected from the persons who have 
recovered from Covid-19 may contain antibodies against SARS-CoV-2, which may 
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be used as a treatment tool. A case series was done in China where 5 critically ill 
patients with confirmed Covid-19 and Acute respiratory distress syndrome (ARDS) 
were selected. [57] They received two consecutive transfusions of 200 mL to 
250 mL of convalescent plasma (total dose: 400 mL) with a SARS-CoV-2-specific 
antibody (IgG) titer more than 1:1,000. After receiving the plasma, the SOFA score 
of the patients decreased and ventilator parameters of the patients (pO2/FiO2 ratio) 
of the patient improved, and viral load decreased by day 12. ARDS resolved in four 
patients by Day 12 and 3 were weaned off the ventilators by 2 weeks. Further trials 
are needed the study the effectiveness of convalescent plasma. FDA is encouraging 
people who have fully recovered from COVID-19 for at least two weeks to donate 
plasma. FDA had issued guidance providing recommendations to health care 
providers & investigators on administration and study of COVID-19 convalescent 
plasma during the public health emergency. FDA issued a EUA for convalescent 
plasma on August 23, 2020, although convalescent plasma did not show any stop-
page of progression to severe COVID-19 or all-cause mortality in the PLACID trial. 
[58, 59] In a trial published in NEJM in November 2020, in 228 patients receiv-
ing convalescent plasma and 105 receiving placebo at 30 days, there was not any 
significant difference among the clinical outcome distribution (odds ratio [OR], 
0.83 (95% CI, 0.52–1.35; P = 0.46). Mortality in the plasma group was 10.96% as 
compared to 11.43% in the placebo group [risk difference 0.46% points (95% CI, 
−7.8 to 6.8). [60]
2.9 Favipiravir
Favipiravir (FPV) is a purine nucleotide that inhibits viral RNA polymerase. 
It was initially used against Ebola but later found to have in-vitro activity against 
other RNA viruses. The EC50 (concentration of a drug that gives half-maximal 
response) of FPV against SARS-CoV-2 in vitro in Vero E6 cells was found to be 
61.88 μM/L. [6, 61] A study investigated the effect of FPV vs. lopinavir/ritonavir 
on the treatment of COVID-19. FPV was independently associated with faster viral 
clearance and a higher improvement rate in chest imaging. These findings suggest 
that FPV has significantly better treatment effects on COVID-19 in terms of disease 
progression and viral clearance as compared with lopinavir/ritonavir. [62] In an 
RCT on moderate to severe COVID patients, FPV was compared with umifenovir 
(Arbidol) by measuring the clinical recovery at 7 days. [63] Results showed no 
significant differences between the 2 groups. At present, there are no recommenda-
tions for the use of FPV in Covid-19 patients. Just like HCQ & lopinavir/ritonavir 
combination, it also causes QT prolongation. [20]
2.10 Ribavirin
Ribavirin, a guanine analog, inhibits viral RNA dependent RNA polymerase 
(RdRp). It has demonstrable activity against many coronaviruses, but when used 
against SARS-CoV it was found to have less effectiveness in vitro requiring higher 
doses with combination therapy. When used with interferon in the treatment of 
MERS-CoV, no benefits were observed in terms of clinical outcomes or the rate of 
virus clearance. [64] Ribavirin also causes dose-dependent hematological toxicity 
& transaminase elevation when used in SARS patients and being a teratogen, is 
contraindicated in pregnancy. [65, 66] A recent trial showed ribavirin not being 
associated with better negative conversion times for the SARS-CoV-2 test and not 
being associated with improved mortality rates. [67] Due to its lack of demonstrable 
efficacy against other coronaviruses and high toxicity profile, it has got a limited 
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role in the treatment of Covid-19. However, its combination with other antivirals is 
being tried in the SEV trial, the result of which is yet to be published. [68]
2.11 Interferons
Studies with interferon-β had shown its activity against MERS. Most studies 
involved combination therapy with lopinavir/ritonavir or ribavirin. However, 
there was no concrete evidence showing its effect on SARS- CoV-2 in-vitro and 
the lack of clinical trials precluded the justification for its use in Covid-19 patients 
and hence there are no recommendations regarding its use. [69] In a study, it was 
shown that early triple antiviral therapy with lopinavir/ritonavir, ribavirin, and 
interferon beta-1b was safe and superior to lopinavir-ritonavir combinations alone 
in alleviating symptoms and shortening the duration of viral shedding and hospital 
stay in patients with mild to moderate COVID-19. [70] In a trial utilizing interferon 
β-1a, clinical response time was not significantly different between interferon and 
the control groups (9.7 ± 5.8 versus 8.3 ± 4.9 days, respectively, P = 0.95). On day 
14, 66.7% versus 43.6% of patients in the interferon group and the control group 
respectively was discharged (OR, 2.5; 95% CI, 1.05–6.37). The 28-day overall 
mortality was significantly less in the interferon than the control group (19% versus 
43.6%, respectively, P = 0.015). Early administration significantly decreased mor-
tality (OR, 13.5; 95% CI, 1.5–1.18). [71] Another trial testing interferon β-1b showed 
its effectiveness in reducing the clinical improvement time without any serious 
adverse events in severe COVID-19 patients. ICU admission and invasive ventilation 
need also decreased following administration of interferon β-1b. [72] The Lancet 
Respiratory Medicine showed the results of an RCT of nebulized interferon beta-
1a in 101 adults admitted to the hospital with COVID-19. It demonstrated better 
odds of clinical improvement than placebo (OR 2·32 [95% CI 1·07–5·04]; p = 0·03). 
No significant difference was there in the hospital discharge odds by day 28. [73] 
Recently, the SOLIDARITY trial also showed no benefit of interferon therapy. [74]
2.12 Corticosteroids
ARDS is a leading cause of mortality in Covid-19 pneumonia. Cytokine storm 
plays a key role in the pathogenesis of ARDS in Covid-19 patients and thus immuno-
suppression may have a role in the treatment of such patients. [75] Glucocorticoids 
modify the inflammation-mediated lung injury and hence can alter progression 
to respiratory failure and death. Studies on SARS and MERS showed that corti-
costeroids did not show any improvement in overall survival but showed delayed 
viral clearance from the respiratory tract and other steroid-related complications 
like Hyperglycaemia & Psychosis. [76] A retrospective study was carried out in 
Covid-19 patients in China who had developed ARDS. Those who received steroids 
had decreased death rates compared to those who did not. [77] In another study in 
non-ARDS patients, corticosteroid treatment did not influence virus clearance time, 
hospital length of stay, or duration of symptoms in mild COVID-19. Another study 
reported that early application of low-dose corticosteroid improves the treatment 
effect, presenting as improvement of hypoxia and fever, shortening disease course, 
and accelerating focus absorption. [78] Steroids are now the only therapy showing 
mortality benefit in COVID-19 severe disease. RECOVERY trial has concluded that 
dexamethasone 6 mg given once daily for up to 10 days decreased 28-day mortality 
in patients with COVID-19 on respiratory support. But a careful decision has to be 
made regarding severity as patients not requiring oxygen showed no benefit but had 
a possibility of harm with corticosteroid therapy. In the dexamethasone group, the 
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incidence of death was less than the usual care group among patients receiving inva-
sive mechanical ventilation (29.3% vs. 41.4%; rate ratio, 0.64; 95% CI, 0.51–0.81) 
and those receiving oxygen without invasive mechanical ventilation (23.3% vs. 
26.2%; rate ratio, 0.82; 95% CI, 0.72–0.94). No benefit was demonstrated among 
those who were receiving no respiratory support at randomization (17.8% vs. 14.0%, 
rate ratio, 1.19; 95% CI, 0.91–1.55). [79] Subsequent RCTs also confirmed the same. 
Hence, all guidelines advocated steroids as first-line therapy in severe COVID-19. In 
due course, specific dose, route, and duration of therapy will be answered.
2.13 Monoclonal antibodies
Various novel monoclonal antibodies are under investigation for COVID-19. In a 
study published in NEJM, it has been described that LY-CoV555 (bamlanivimab) (also 
known as LY3819253), is a potent anti-spike neutralizing monoclonal antibody. [80] 
It binds to the receptor-binding domain of SARS-CoV-2. It was extracted from the 
convalescent plasma obtained from a COVID-19 patient. The protection of bamla-
nivimab against SARS-CoV-2 in primates has been reported. [81] In the interim analy-
sis of data, patients receiving LY-CoV555 reported fewer hospitalizations and a lesser 
symptom burden than placebo receivers. In November 2020, it got the FDA EUA. [82] 
According to FDA, bamlanivimab reduced COVID-19 related hospital admissions in 
patients who are at high risk for disease progression. [83] This authorization came 
even after the company making the drug, Lilly, had announced in October 2020 that it 
was holding the trial in the hospital admitted patients as it not showing any benefits in 
them (ACTIV-3 trial). Remaining studies of bamlanivimab remain ongoing, includ-
ing ACTIV-2 trial which includes the newly diagnosed mild to moderate COVID-19 
patients; BLAZE-1, including recently diagnosed COVID-19 patients in the ambula-
tory (non-hospitalized) setting, studying bamlanivimab as monotherapy and in 
combination with etesevimab; and BLAZE-2, a phase 3 study for COVID-19 pro-
phylaxis. Based on BLAZE-1 data, Lilly had submitted a request for EUA for bamla-
nivimab for the treatment of recently diagnosed mild to moderate COVID-19 patients 
to the FDA. [84] FDA reported 3% hospitalizations and emergency room visits in 
bamlanivimab treated patients compared to 10% in placebo. The FDA has approved 
bamlanivimab for patients age ≥ 12, and at high risk for progressing to severe covid-
19 or hospital admission. However, it is emphasized that bamlanivimab should not 
be given to in-hospital COVID-19 patients or those requiring oxygen therapy; as such 
monoclonal antibodies may worsen outcomes in these patients. Another potential 
antibody treatment for COVID-19, REGN-COV2, a combination of two monoclonal 
antibodies casirivimab and imdevimab (REGN10933 and REGN10987), also faced 
some issues among inpatients with high oxygen requirements. In November 2020, the 
FDA issued EUA to monoclonal antibodies casirivimab and imdevimab (REGN10933 
and REGN10987- against spike proteins of SARS-CoV-2) to be administered together 
for the treatment of mild to moderate COVID-19 in adults and pediatric patients 
(≥12 years of age). [85] Although, in this case also, Regeneron Pharma had to halt its 
antibody cocktail trial in the admitted patients due to safety concerns, hence it was 
approved for non-admitted patients only. [86] Interestingly, US President Donald 
Trump had also received this regime when he tested positive for COVID-19. [87] 
Astra Zeneca’s COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 
trial has also advanced into Phase III. [88] On February 9, 2021, the FDA has issued 
a EUA for bamlanivimab plus etesevimab for the management of mild to moderate 
COVID-19 in outpatients at high risk for disease progression. The data come from a 
randomized, double-blind, placebo-controlled clinical trial in 1,035 non-hospitalized 
adults with mild to moderate COVID-19, at high risk for progression to severe dis-
ease. Hospitalization or death occurred in 36 (7%) of placebo recipients compared 
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to 11 (2%) patients treated with bamlanivimab 2,800 milligrams and etesevimab 
2,800 milligrams administered together, demonstrating a 70% reduction. [89]
2.14 Janus kinase (JAK) inhibitors
The kinase inhibitors are being proposed as a novel modality of COVID-19 treat-
ment. The rationale behind this being the prevention of phosphorylation of key pro-
teins that are involved in the signal transduction that in turn leads to immunological 
activation and inflammation. This includes the cellular responses to the pro-inflam-
matory cytokines like IL-6. [90] JAK inhibitors interfere with the phosphorylation 
of signal transducer and activator of transcription (STAT) proteins. [91, 92] These 
proteins are in turn involved in cell signaling, growth, and survival. The immunosup-
pression may reduce the hyperactive immune state induced by COVID-19. Moreover, 
JAK inhibitors like baricitinib have a theoretical direct antiviral activity via interfer-
ence with viral endocytosis. This can prevent viral entry in the cells. [93] NIH has 
recommended that in the rare circumstances where corticosteroids cannot be used, 
baricitinib in combination with remdesivir may be used for the treatment of hospital-
ized, non-intubated patients requiring oxygen supplementation. IDSA guidelines also 
suggest the use of this combination in hospitalized severe COVID-19 patients. [47] 
Use of baricitinib without remdesivir is not recommended, except in a clinical trial. 
[94] As for the use of baricitinib in combination with corticosteroids, there is still 
insufficient data. Both baricitinib and corticosteroids cause immuno-suppression; 
hence, there is an additive risk of infection.
2.15 Other miscellaneous drugs with a possible therapeutic effect
In the pathogenesis of Covid-19, ACE 2 receptors play an important role by 
facilitating the entry of the virus into the cell. [1, 95] Thus it could be a possible 
therapeutic target with the use of ACE-inhibitors and ARB. [1, 96] However, there 
is a concern that the use of these drugs to stop virus replication may increase the 
expression of ACE-2 receptors and paradoxically worsen the infection. However, 
no in-vitro studies are available which show either definite detrimental or protec-
tive effect of these agents. As a result, the current guidelines state to continue these 
drugs in patients who are already taking them. [97]
Umifenovir (also known as Arbidol) is an antiviral agent with a unique mecha-
nism of action targeting the S protein/ACE2 interaction and inhibiting membrane 
fusion of the viral envelope. [98] It is approved in Russia for prophylaxis and treat-
ment of influenza. Of particular interest is its demonstrable in-vitro activity against 
Covid-19. [99] In an observational study in China, patients treated with umifenovir 
for a median duration of 9 days had a higher discharge rate and lesser mortality. 
[100] But as with other agents, the lack of RCT limits the justification for its use in 
Covid-19. However, ACE targeting therapy is a promising one. [1]
Camostat mesylate is an agent used in the treatment of pancreatitis. It inhibits 
host serine protease, TMPRSS2.3, and has been shown to prevent viral cell entry 
in-vitro and thus could be a target for future studies. [101]
Nitazoxanide, an anti-helminthic with a relatively favorable safety profile has 
shown in-vitro activity against SARS-CoV and MERS. [102] Besides it also has addi-
tional immunomodulatory action & thus can be used in trials in Covid-19 patients 
as a therapeutic option.
Many non-allopathic pharmaceuticals are also in pipeline as promising COVID-19  
therapy. In June 2020, yoga guru Baba Ramdev announced that his company Patanjali 
Ayurved had launched a drug called ‘Coronil’ that could cure COVID-19. [103] 
However, no scientific basis for this claim is produced until now.
Fighting the COVID-19 Pandemic
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3. Conclusion
The Global pandemic with COVID-19 is on. Drug therapy holds the key to the 
treatment and containment of the disease. Hence, large-scale multicentric trials are 
ongoing involving multiple drugs. Until now, no therapy is absolutely effective in 
the treatment of the patient as infection and death rates continue to mount all over 
the world. Corticosteroids have shown a significant effect on reducing the mortality 
in severe COVID-19 patients. It is hoped that the results of the ongoing trials will 
open further opportunities towards understanding the disease process and  
designing safe and effective treatments.
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